Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. / Rauch, Thomas; Graefe-Mody, Ulrike; Deacon, Carolyn F; Ring, Arne; Holst, Jens Juul; Woerle, Hans-Juergen; Dugi, Klaus A; Heise, Tim.

In: Diabetes Therapy, Vol. 3, No. 1, 11.2012, p. 10.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rauch, T, Graefe-Mody, U, Deacon, CF, Ring, A, Holst, JJ, Woerle, H-J, Dugi, KA & Heise, T 2012, 'Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus', Diabetes Therapy, vol. 3, no. 1, pp. 10. https://doi.org/10.1007/s13300-012-0010-y

APA

Rauch, T., Graefe-Mody, U., Deacon, C. F., Ring, A., Holst, J. J., Woerle, H-J., ... Heise, T. (2012). Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Therapy, 3(1), 10. https://doi.org/10.1007/s13300-012-0010-y

Vancouver

Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle H-J et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Therapy. 2012 Nov;3(1):10. https://doi.org/10.1007/s13300-012-0010-y

Author

Rauch, Thomas ; Graefe-Mody, Ulrike ; Deacon, Carolyn F ; Ring, Arne ; Holst, Jens Juul ; Woerle, Hans-Juergen ; Dugi, Klaus A ; Heise, Tim. / Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. In: Diabetes Therapy. 2012 ; Vol. 3, No. 1. pp. 10.

Bibtex

@article{c3292bcbdbe44b9193462a04737ba585,
title = "Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus",
abstract = "Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.",
author = "Thomas Rauch and Ulrike Graefe-Mody and Deacon, {Carolyn F} and Arne Ring and Holst, {Jens Juul} and Hans-Juergen Woerle and Dugi, {Klaus A} and Tim Heise",
year = "2012",
month = "11",
doi = "10.1007/s13300-012-0010-y",
language = "English",
volume = "3",
pages = "10",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

AU - Rauch, Thomas

AU - Graefe-Mody, Ulrike

AU - Deacon, Carolyn F

AU - Ring, Arne

AU - Holst, Jens Juul

AU - Woerle, Hans-Juergen

AU - Dugi, Klaus A

AU - Heise, Tim

PY - 2012/11

Y1 - 2012/11

N2 - Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.

AB - Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.

U2 - 10.1007/s13300-012-0010-y

DO - 10.1007/s13300-012-0010-y

M3 - Journal article

VL - 3

SP - 10

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 1

ER -

ID: 45841462